To read the full story, subscribe or sign in.

Curevac tops up with $29.5M financing as prostate cancer trial readout nears

Nov. 9, 2016

Messenger RNA (mRNA) drug developer Curevac AG added $29.5 million in new funds to its coffers from German investors looking to support the Tübingen-based home team in a hot field defined by sizable early investments.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 21, 2025.

Coinfections and diversity paint the many shades of HIV cure

BioWorld

We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...

Engineered IL-18 variants with improved drug-like properties show promise for cancer immunotherapy

BioWorld Science

Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in promoting antitumor immunity by activating T and natural killer (NK) cells....

For big pharma, China is a shopper’s dream

BioWorld

Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing...